Rousselot has been awarded European, Japanese and Chinese patents for Colartix, a hydrolysed cartilage matrix with science on joint discomfort relief.
Specifically designed for joint care, Colartix is now patented as Collagen hydrolysate composition to reduce joint pain after exercise. It is a unique matrix of collagen peptides and chondroitin sulfate.
“These new patents are a milestone that underscores our commitment and ability to innovate in the collagen industry,” said Jeroen Colpaert, Executive Vice President, Rousselot.
"They not only provide exclusive protection to our Colartix customers but also strengthen their product appeal to consumers through association with proven innovation and trust,” Colpaert said.
The ingredient is supported by scientific research demonstrating its efficacy in alleviating joint discomfort across gender, age and sport intensity.
This has led it to gain strong market traction since its launch in 2022.
Colartix can be widely incorporated into dietary supplements and supports both active individuals and those experiencing wear and tear due to ageing or excess weight.
This demand aligns with the joint health supplement market, which hit $4.4bn in 2024 and is set to grow 2.4% annually through 2029.
Colartix only needs 1 gram of daily intake to deliver its benefits, and is a natural, safe and easy-to-use ingredient.
This small daily dosage and its ability to blend seamlessly with other ingredients make it ideal for a variety of applications, including capsules, powder supplements, tablets and shots.
The European patent, granted by the European Patent Office, is registered under the number EP4465823B1.
The Japanese patent, issued by the Japan Patent Office, holds the number JP7690140B2.
The Chinese patent, granted by the China National Intellectual Property Administration, is registered under number CN118829360.
Patent applications for Colartix are also pending in Brazil and the United States.